Chimeric Antigen Receptor Selectivity - v1
Research type
Research Study
Full title
Exploring the mechanism of chimeric antigen receptor target selectivity
IRAS ID
191919
Contact name
John James
Contact email
Sponsor organisation
University of Cambridge
Duration of Study in the UK
2 years, 0 months, 30 days
Research summary
A new class of anti-cancer therapeutics called chimeric antigen receptors (CARs) are showing promise in redirecting our own immune system to target and kill tumour cells. However, the cancer marker that these CARs recognise is often also present on healthy cells too, although usually at a lower level. The CARs are currently unable to discriminate between the two cells and so often cause the death of these normal cells too.
We hypothesise that a simple modification of the CAR structure might allow it to more readily achieve this discrimination, and so make them more effective therapeutics.
REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
15/WM/0429
Date of REC Opinion
18 Nov 2015
REC opinion
Favourable Opinion